🟢 BioXcel Therapeutics is trading 5.6% up in pre-market after positive Phase 3 SERENITY At-Home data

BioXcel Therapeutics is trading 5.6% up now at $0.87 after investors responded to positive Phase 3 SERENITY At-Home data presented on August 19, 2026.

• Analysts raised the fair-value estimate to approximately $18.33 per share from $14, a 31% increase.
• XBI is up 2.27% pre-market after major cancer-trial successes.
• Financing remains a material risk ahead of BioXcel’s lender deadline on August 21, 2026.